KYV-101

Donanemab's enhanced titration method significantly reduces ARIA-E frequency and severity while maintaining amyloid reduction in Alzheimer's patients.

The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies.

KYV-101, an experimental cell therapy, has been granted orphan drug status by the European Medicines Agency for the treatment of myasthenia gravis (MG).

The multiple sclerosis (MS) therapeutic landscape is expanding, with over 80 active pipeline therapies currently in development by more than 75 companies.

The gene therapy market is experiencing substantial growth, fueled by technological advancements, increased investments, and a deeper understanding of genetic diseases.